An injectable pharmaceutical composition comprising particles of an isoxazoline compound of Formula wherein R 1 is halogen, CF 3, OCF 3, or CN; n is an integer from 0 up to and including 3, m is 1 or 2; R 2 is C 1 -C 3 haloalkyl, CF 3 or CF 2 Cl T is a 5, or 6 membered ring, or bicyclic, which is optionally substituted by one or more radicals Y; Y is methyl, halomethyl, halogen, CN, NO 2, NH 2 -C=S, or two adjacent radicals Y together form a chain; Q is X-NR 3 R 4, NR 3 -NR 3 -X-R 3, X-R 3, or a 5-membered N-heteroaryl ring, which is optionally substituted by one or more radicals; X is CH 2, CH(CH 3), CH, CO, CS; R 3 is hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl, methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuryl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, cycloalkyl, wherein Z A is hydrogen, halogen, cyano, or halomethyl; R 4 is hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl; R 5 is H, alkyl, or haloalkyl; R 6 is H, alkyl, or haloalkyl; or wherein R 3 and R 4 together form a substituent selected from the group consisting of: and or a salt or N-oxide thereof and a pharmaceutical acceptable excipient wherein the isoxazoline compound is in suspension in the composition and wherein the isoxazoline compound has a volume weighted particle size distribution D50 as measured by a static light scattering instrument of from 50 microns (μm) to 150 microns (μm). R 1 is halogen, CF 3, OCF 3, or CN; n is an integer from 0 up to and including 3, m is 1 or 2; R 2 is C 1 -C 3 haloalkyl, CF 3 or CF 2 Cl T is a 5, or 6 membered ring, or bicyclic, which is optionally substituted by one or more radicals Y; Y is methyl, halomethyl, halogen, CN, NO 2, NH 2 -C=S, or two adjacent radicals Y together form a chain; Q is X-NR 3 R 4, NR 3 -NR 3 -X-R 3, X-R 3, or a 5-membered N-heteroaryl ring, which is optionally substituted by one or more radicals; X is CH 2, CH(CH 3), CH, CO, CS; R 3 is hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl, methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuryl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl, alkylsulfanylalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, cycloalkyl, wherein Z A is hydrogen, halogen, cyano, or halomethyl; R 4 is hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl; R 5 is H, alkyl, or haloalkyl; R 6 is H, alkyl, or haloalkyl; or wherein R 3 and R 4 together form a substituent selected from the group consisting of: and or a salt or N-oxide thereof and a pharmaceutical acceptable excipient wherein the isoxazoline compound is in suspension in the composition and wherein the isoxazoline compound has a volume weighted particle size distribution D50 as measured by a static light scattering instrument of from 50 microns (μm) to 150 microns (μm).